Zimmer Biomet (ZBH) Stock Price, News & Analysis

Company Overview

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) is a medical technology company that develops, manufactures and markets products designed to treat musculoskeletal conditions. Its portfolio includes orthopedic implants and related systems for hip, knee, shoulder and other joint replacements, as well as products used in sports medicine, extremity care and trauma procedures.

The company also provides robotic- and computer-assisted surgical technologies, digital solutions and other tools intended to support orthopedic procedures and patient care. Zimmer Biomet sells its products to hospitals, ambulatory surgery centers and healthcare professionals through direct sales organizations and distributors.

Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet serves healthcare providers and patients in the United States and international markets. The company was formed through the combination of Zimmer Holdings and Biomet in 2015. Ivan Tornos has served as Zimmer Biomet’s president and chief executive officer since 2023.

Key Stats

• Today's Range: $93.72 to $96.17
• 50-Day Range: $88.79 to $101.41
• 52-Week Range: $79.12 to $106.88
• Volume: 3.95 million shs
• Average Volume: 1.64 million shs
• Market Capitalization: $18.20 billion
• P/E Ratio: 23.22
• Dividend Yield: 1.01%
• Price Target: $103.00
• Consensus Rating: Hold

Zimmer Biomet Stock Analysis - MarketRank™

Zimmer Biomet scored higher than 74% of companies evaluated by MarketBeat, and ranked 160th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.7 / 5
• Analyst Rating: Hold

Consensus Rating

Zimmer Biomet has received a consensus rating of Hold. The company's average rating score is 2.18, and is based on no strong buy ratings, 6 buy ratings, 14 hold ratings, and 2 sell ratings.

Upside/Downside

The consensus price target for Zimmer Biomet is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Zimmer Biomet has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 5.27%

Earnings Growth

Earnings for Zimmer Biomet are expected to grow by 5.27% in the coming year, from $8.54 to $8.99 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Zimmer Biomet is 23.22, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.67.

Price to Earnings Ratio vs. Sector

The P/E ratio of Zimmer Biomet is 23.22, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.49.

Price to Earnings Growth Ratio

Zimmer Biomet has a PEG Ratio of 1.80. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Zimmer Biomet has a P/B Ratio of 1.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.67% of the float of Zimmer Biomet has been sold short.

Short Interest Ratio / Days to Cover

Zimmer Biomet has a short interest ratio ("days to cover") of 6.48.

Change versus previous month

Short interest in Zimmer Biomet has recently decreased by 0.08%, indicating that investor sentiment is improving.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Zimmer Biomet pays a meaningful dividend of 1.01%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Zimmer Biomet does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Zimmer Biomet is 23.36%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Zimmer Biomet will have a dividend payout ratio of 10.68% next year. This indicates that Zimmer Biomet will be able to sustain or increase its dividend.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.66

News Sentiment

Zimmer Biomet has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Zimmer Biomet this week, compared to 6 articles on an average week.

Search Interest

Only 2 people have searched for ZBH on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

MarketBeat Follows

4 people have added Zimmer Biomet to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Zimmer Biomet insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $824,028.00 in company stock.

Percentage Held by Insiders

1.28% of the stock of Zimmer Biomet is held by insiders.

Percentage Held by Institutions

88.89% of the stock of Zimmer Biomet is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Record date for 7/31 Dividend: 6/25/2026
• Ex-Dividend for 7/31 Dividend: 6/25/2026
• Dividend Payable: 7/31/2026
• Last Earnings: 8/05/2026
• Today: 9/20/2026
• Record date for 10/30 Dividend: 9/30/2026
• Ex-Dividend for 10/30 Dividend: 9/30/2026
• Dividend Payable: 10/30/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NYSE:ZBH
• Previous Symbol: NYSE:ZMH
• CIK: 1136869
• Web: www.zimmerbiomet.com
• Phone: (574) 267-6131
• Fax: 574-372-4988
• Employees: 17,000
• Year Founded: 1927

Price Target and Rating

• Average Price Target for Zimmer Biomet: $103.00
• High Price Target: $120.00
• Low Price Target: $90.00
• Potential Upside/Downside: +7.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.18
• Research Coverage: 22 Analysts

Profitability

• EPS (Trailing Twelve Months): $4.11
• Trailing P/E Ratio: 23.22
• Forward P/E Ratio: 11.17
• P/E Growth: 1.8
• Net Income: $705.20 million
• Net Margins: 9.48%
• Pretax Margin: 10.97%
• Return on Equity: 13.12%
• Return on Assets: 7.23%

Debt

• Debt-to-Equity Ratio: 0.50
• Current Ratio: 1.69
• Quick Ratio: 0.94

Sales & Book Value

• Annual Sales: $8.23 billion
• Price / Sales: 2.21
• Cash Flow: $13.75 per share
• Price / Cash Flow: 6.94
• Book Value: $64.11 per share
• Price / Book: 1.49

Miscellaneous

• Outstanding Shares: 190,740,000
• Free Float: 188,297,000
• Market Cap: $18.20 billion
• Optionable: Optionable
• Beta: 0.47